Practice Points:
Consider who writes the guideline. Specialist-heavy panels bring expertise but may favor intervention, particularly when evidence is limited.
Look at the strength of evidence behind strong recommendations. In this guideline, only ~20 percent of Class I recommendations are supported by high-quality data; many rely on expert opinion.
Question screening without a clear action plan. Lipid screening from ages 19 to 29 precedes the ability to calculate risk, with little guidance on management.
Use risk calculators as a starting point, not a playbook. PREVENT estimates omit important modifiers, including both risk enhancers and reducers.
Consider where a patient’s risk comes from. Treatment decisions should reflect the underlying drivers of risk (e.g., low-density lipoprotein [LDL] vs. blood pressure), not just a composite score.
Don't equate "net benefit" with meaningful benefit. Small absolute risk reductions (e.g., NNT ≥ 100 over 10 years) may not justify treatment for many patients.
Apply the "CPR" framework thoughtfully. Calculate risk, personalize with clinical context, and reclassify when appropriate, but use clinical judgment at each step.
Use screening and additional testing selectively. Focus on situations wherein results are likely to change management.
Maintain lifestyle counseling as the foundation. This applies regardless of risk score, test results, or medication decisions.
Treat guidelines as guides, not directives. The goal is to inform care, not replace individualized clinical judgment.
EBM Focus Article:
The previous EBM Focus article summarized the latest American College of Cardiology/American Heart Association (ACC/AHA) guideline on management of dyslipidemia. This important guideline will shape how millions of patients are treated and hopefully help them live better and longer. Notably, primary care providers are likely to be the ones making most of the treatment recommendations and leading discussions with patients about benefits and harms of screening and pharmacotherapy. As guidelines continue to evolve, it’s critical to have access to the most current recommendations at the point of care—DynaMedex topics, such as Hypercholesterolemia, are continuously updated with the latest evidence and guideline changes to support clinical decision-making in real time.
In the current EBM Focus, the intent is to offer some considerations from a primary care perspective as providers think about how to apply these recommendations in everyday clinical practice.
How well does the evidence support the recommendations?
The first consideration is the composition of the guideline development group, the perspectives represented, and how strongly recommendations are supported by evidence. In this case, cardiologists represent the majority of voices on the panel, which brings expertise in managing dyslipidemia and experience in conducting major clinical trials but perhaps also brings a more narrowly-focused view of the patient. Specialists, in general, may be more inclined toward intervention when evidence is weak or uncertain. In this guideline, only about 20 percent of Class I (strong) recommendations are supported by high-quality evidence, while roughly half rely on limited data or expert opinion. This raises the possibility of expert-driven bias. For example, the recommendation to measure lipoprotein(a) (Lp[a]) once in all adults is not supported by trial data demonstrating improved outcomes. The rationale appears to be that identifying elevated genetic risk could prompt earlier prevention efforts. Although this sounds perfectly reasonable, the history of medicine is peppered with ideas that sounded good in theory but actually wound up being harmful once studied with high-quality trials. In practice, it is already recommended to advise all patients to engage in healthy behaviors. It is also easy to imagine unintended consequences, such as a patient taking a normal Lp(a) to mean they are at low risk and deprioritizing lifestyle change. A more targeted approach, such as testing those with a strong family history, may be more practical and conscious of the growing economic health care burden.
Decisions are rarely based solely on whether benefits slightly exceed harms. Magnitude of benefit, potential harms, cost, pill burden, and patient preferences all matter.
Decisions are rarely based solely on whether benefits slightly exceed harms. Magnitude of benefit, potential harms, cost, pill burden, and patient preferences all matter.
How should screening, risk calculation, and treatment threshold recommendations be implemented in practice?
Another concern is the recommendation for lipid screening beginning at age 19, paired with treatment decisions based on 10-year atherosclerotic cardiovascular disease (ASCVD) risk that cannot be calculated with the PREVENT equations until age 30. This creates a gap: widespread testing without clear guidance on how results should change management. For primary care clinicians, this adds to an already long to-do list without clear evidence, or even consensus, about what to do with most findings beyond reinforcing lifestyle counseling, which should already be routine. Notably, there are no randomized trials comparing outcomes with screening starting at age 19 versus age 30.
The guideline also acknowledges that risk calculators do not incorporate all relevant factors but focus primarily on "risk enhancers." It gives little attention to factors that reduce risk. For example, consider two patients with identical clinical profiles and PREVENT calculated risk, but one had a father who died of a myocardial infarction at age 54 and the other has both parents alive in their 90s. The statement that the absence of risk enhancers does not imply risk lower than the calculated estimate is also difficult to reconcile with basic reasoning: If some individuals have upward risk modifiers, then those without them must, on average, have lower risk.
Additionally, the source of ASCVD risk matters as we consider sources of treatment. Per the guideline, a statin is recommended for elevated ASCVD risk, even if LDL is 50 mg/dL and the real source of risk is a systolic blood pressure (SBP) of 180 mmHg. Imagine if a patient had an LDL of 210 mg/dL and an SBP of 120 mm Hg and the recommendation was to start amlodipine—that would be ludicrous! Nuance must be considered and discussed with patients, along with, or despite, the specific risk percentages that can be provided with PREVENT.
Concerns also arise around treatment thresholds. The guideline suggests considering therapy at a three percent 10-year risk based on a “net benefit” framework—defined as cardiovascular benefit outweighing the risk of statin-associated diabetes. However, treating any point of marginal net benefit as a threshold for intervention overlooks the importance of several factors: effect size, source of risk, cost, and patient values. At a three percent 10-year risk, the absolute risk reduction is about -0.66% with a statin, or an NNT of 150. Knowledge of the real magnitude of benefit may affect treatment decisions for some patients and is worth discussing. In addition, as one considers starting pharmacotherapy in younger patients, decisions about whether to begin medications take on added importance when one considers the cumulative effect potentially over decades—both beneficial and harmful—of pharmacotherapy in this age group.
Decisions are rarely based solely on whether benefits slightly exceed harms. Magnitude of benefit, potential harms, cost, pill burden, and patient preferences all matter. While the guideline emphasizes shared decision-making, much of the discussion focuses on identifying factors that support treatment rather than helping patients decide whether treatment aligns with their goals.
Does the guideline get it right when it comes to dietary supplements?
Finally, the guideline addresses dietary supplements, noting that berberine, garlic/onion, turmeric, and red yeast rice may have lipid-lowering effects, while cinnamon has not shown benefit. It cites the SPORT trial, in which rosuvastatin was clearly superior to fish oil, cinnamon, garlic, turmeric, plant sterols, and red yeast rice, and none of these supplements outperformed placebo. Based on these findings, the guideline gives a Level 3 recommendation against the use of supplements for lipid lowering, citing limited and inconsistent evidence.
However, berberine was not included in the SPORT trial. Multiple systematic reviews have found that berberine produces clinically meaningful reductions in LDL cholesterol, in some cases comparable to simvastatin, with greater reductions in triglycerides. In addition, berberine has been associated with reductions in HbA1c, an effect that contrasts with the modest increases seen with statins. The guideline’s broad recommendation against supplements, while briefly acknowledging berberine’s potential benefit, does not fully engage with this body of evidence.
How should the ACC/AHA guidelines be implemented in primary care?
All told, primary care providers play a critical role in understanding the many dimensions that need to be taken into account when considering the patient in front of them. The “CPR Method” suggested in the guideline—Calculate 10-year ASCVD risk using the PREVENT equation, Personalize the estimated risk considering patient-specific risk enhancers (and risk reducers), and consider Reclassifying risk with CAC when uncertainty about treatment remains—is a reasonable way to understand and communicate baseline risk, absolute benefits and harms, and to incorporate patient preferences into decisions about starting or deferring treatment. Lifestyle counseling remains foundational regardless of risk category or test results. Screening and additional testing should be used selectively, particularly when results are likely to change management.
The ACC/AHA dyslipidemia guideline represents a thoughtful, good-faith effort by a group of knowledgeable clinicians and researchers to synthesize a complex and evolving evidence base. It provides a useful framework and reflects a great deal of expertise in cardiovascular risk reduction. The concerns raised here are less about the intent or rigor of the work and more about how the recommendations may be interpreted and applied in practice.
In several areas, the certainty of the recommendations seems to outpace the strength or completeness of the underlying evidence, and the nuance inherent in the data may be difficult to convey (or easy to overlook) in busy clinical settings. Primary care clinicians are left to reconcile population-level guidance with individual patient contexts wherein differences in baseline risk, preferences, and tolerance for treatment matter.
Ultimately, this guideline, like most, should be used to guide clinical care. The opportunity, and responsibility, for primary care providers is to use these recommendations as a starting point, while maintaining a clear focus on individualized decision-making, careful communication of absolute benefits and harms, and respect for what matters most to each patient.
For more information, see the topic Hypercholesterolemia in DynaMedex.
